0343 management and program analysis

Bristol Myers Squibb – Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early

Leonardo Rasaki 2 weeks ago

Long-term data continue to reinforce benefits of Opdivo (nivolumab)-based combinations Response outcomes data continue to build upon the clinical evidence of Opdualag (nivolumab and relatlimab-rmbw) in advanced melanoma Exploratory analyses in non-small cell lung cancer and urothelial carcinoma support the potential benefit of immunotherapy in earlier stages of cancer PRINCETON, […]